ATOSSA THERAPEUTICS INC (ATOS)

US04962H5063 - Common Stock

1.53  +0.01 (+0.66%)

Premarket: 1.55 +0.02 (+1.31%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ATOS. ATOS was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ATOS as it has an excellent financial health rating, but there are worries on the profitability. ATOS is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

In the past year ATOS has reported negative net income.
ATOS had a negative operating cash flow in the past year.
In the past 5 years ATOS always reported negative net income.
ATOS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ATOS's Return On Assets of -31.27% is fine compared to the rest of the industry. ATOS outperforms 71.50% of its industry peers.
ATOS has a better Return On Equity (-33.06%) than 79.69% of its industry peers.
Industry RankSector Rank
ROA -31.27%
ROE -33.06%
ROIC N/A
ROA(3y)-22.56%
ROA(5y)-47.75%
ROE(3y)-23.61%
ROE(5y)-56.71%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ATOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

9

2. Health

2.1 Basic Checks

ATOS has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ATOS has been increased compared to 5 years ago.
There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ATOS has an Altman-Z score of 19.27. This indicates that ATOS is financially healthy and has little risk of bankruptcy at the moment.
ATOS has a better Altman-Z score (19.27) than 93.00% of its industry peers.
There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.27
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ATOS has a Current Ratio of 17.61. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 17.61, ATOS belongs to the top of the industry, outperforming 93.69% of the companies in the same industry.
A Quick Ratio of 17.61 indicates that ATOS has no problem at all paying its short term obligations.
ATOS has a Quick ratio of 17.61. This is amongst the best in the industry. ATOS outperforms 93.86% of its industry peers.
Industry RankSector Rank
Current Ratio 17.61
Quick Ratio 17.61

1

3. Growth

3.1 Past

ATOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.57%.
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ATOS will show a very strong growth in Earnings Per Share. The EPS will grow by 71.69% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.06%
EPS Next 2Y-5.87%
EPS Next 3Y42.09%
EPS Next 5Y71.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

ATOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ATOS's earnings are expected to grow with 42.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.87%
EPS Next 3Y42.09%

0

5. Dividend

5.1 Amount

No dividends for ATOS!.
Industry RankSector Rank
Dividend Yield N/A

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (4/26/2024, 7:00:00 PM)

Premarket: 1.55 +0.02 (+1.31%)

1.53

+0.01 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap191.71M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.27%
ROE -33.06%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 17.61
Quick Ratio 17.61
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y